Disease Domain | Count |
---|---|
Neoplasms | 3 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Recombinant protein | 1 |
Target |
Mechanism BPTF inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism P-gp modulators [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism JNK inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date23 Sep 2023 |
Sponsor / Collaborator |
Start Date01 Jul 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
C620-0696 ( BPTF ) | Non-Small Cell Lung Cancer More | Preclinical |
ZYZ384 ( JNK ) | Non-Small Cell Lung Cancer More | Preclinical |
Pomiferin ( P-gp x SERCA x mTOR ) | Lung Cancer More | Preclinical |
CN114796456 ( FBXL16 ) | Inflammation More | Discovery |